The endothelium, platelets, and brain ischemia

Reviews in Neurological Diseases

Volumn 4, Issue 3, 2007, Pages 113-121

  Caplan, Louis R ^a   Fisher, Mark ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antithrombotic therapy; Atherosclerotic plaques; Brain ischemia; Endothelium; Penetrating artery disease

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CILOSTAZOL; CLOPIDOGREL; CYCLIC GMP; DIPYRIDAMOLE; FIBRIN; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; IBUPROFEN; ICOSAPENTAENOIC ACID; INDOMETACIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PHENYLBUTAZONE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN G2; THROMBIN; THROMBOXANE A2; TICLOPIDINE; UNINDEXED DRUG;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN INFARCTION; BRAIN ISCHEMIA; CORONARY STENT; DIARRHEA; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; NEUTROPENIA; OCCLUSIVE CEREBROVASCULAR DISEASE; RASH; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; BRAIN ISCHEMIA; CELL ADHESION; CEREBRAL ARTERIES; ENDOTHELIAL CELLS; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL THROMBOSIS;

EID: 35148898124     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Ryan US. Keynote address: active functions of the endothelium. In: Ginsberg MD, Dietrich WD, eds. Cerebrovascular Diseases, Sixteenth Research (Princeton) Conference. New York: Raven Press; 1989:1-11.
2. Eisert WG, Schlachetzki F. Vascular endothelium and the blood-brain barrier. In: Bogousslavsky J, Fisher M, eds. Stroke: Part 1: Basic and Epidemiological Aspects. Handbook of Clinical Neurology (3rd series); vol 91. In press.
3. Tran ND, Correale J, Schreiber SS, Fisher M. Transforming growth factor-beta mediates astrocyte-specific regulation of brain endothelial anticoagulant factors. Stroke. 1999;30:1671-1678.
4. Caplan LR. Arterial sources of embolism. In: Caplan LR, Manning WJ, eds. Brain Embolism. New York: Informa Healthcare; 2006:203-222.
5. Fisher CM. Occlusion of the internal carotid artery. Arch Neurol. 1951;65:346-377.
6. Hennerici M. The unstable plaque. Cerebrovasc Dis. 2004;17(suppl 3):17-22.
7. Fisher CM, Ojemann RG. A clinico-pathologic study of carotid endarterectomy plaques. Rev Neurol (Paris). 1986;142:573-589.
8. Fisher M, Paganini-Hill A, Martin A, et al. Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis. Stroke. 2005;36:253-257.
9. Heistad DD. Unstable coronary-artery plaques. N Engl J Med. 2003;349:2285-2287.
10. Ogata J, Masuda J, Yutani C, Yamaguchi T. Rupture of the atheromatous plaque as a cause of thrombotic occlusion of stenotic internal carotid artery. Stroke. 1990;21:1740-1745.
11. Ogata J, Masuda J, Yutani C, Yamaguchi T. Mechanisms of cerebral artery thrombosis: histopathological analysis on eight necropsy cases. J Neurol Neurosurg Psychiatry. 1994;57:17-21.
12. del Zoppo GJ. Vacular hemostasis and brain embolism. In: Caplan LR, Manning WJ, eds. Brain Embolism. New York: Informa Healthcare; 2006:243-258.
13. Caplan LR, Hennerici MG. Impaired clearance of emboli (washout) is an important link between hypoperfusion, embolism, and ischemic stroke. Arch Neurol. 1998;55:1475-1482.
14. Caplan LR, Wong K-S, Gao S, Hennerici MG. Is hypoperfusion an important cause of strokes? If so, how? Cerebrovasc Dis. 2006;21:145-153.
15. Marder VJ, Chute DJ, Starkman S, et al. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke. 2006;37:2086-2093.
16. Fisher CM. The arterial lesions underlying lacunes. Acta Neuropathol. 1969;12:1-15.
17. Ostrow PT, Miller LL. Pathology of small artery disease. In: Pullicino PM, Caplan LR, Hommel M, eds. Cerebral Small Artery Disease. New York: Raven Press; 1993:93-123.
18. Caplan LR. Caplan's Stroke: A Clinical Approach, 3rd ed. Burlington, MA: Butterworth-Heinemann; 2000.
19. Caplan LR. Binswanger's disease - revisited. Neurology. 1995;45:626-633.
20. Fisher CM. Binswanger's encephalopathy: a review. J Neurol. 1989;236:65-79.
21. Fisher CM, Caplan LR. Basilar artery branch occlusion: a cause of pontine infarction. Neurology. 1971;21:900-905.
22. Fisher CM. Bilateral occlusion of basilar artery branches. J Neurol Neurosurg Psychiatry. 1977;40:1182-1189.
23. Caplan LR. Intracranial branch atheromatous disease: a neglected, understudied and underused concept. Neurology. 1989;39:1246-1250.
24. Fields WS, Lemak NA. A History of Stroke: Its Recognition and Treatment. New York: Oxford University Press; 1989:115-119.
25. Craven LL. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J. 1953;75:38-44.
26. Craven LL. Prevention of coronary and cerebral thrombosis. Miss Valley Med J. 1956;78:213-215.
27. Mundall J, Quintero P, von Kaulla K, et al. Transient monocular blindness and increased platelet aggregability treated with aspirin - a case report. Neurology. 1971;21:402.
28. Harrison MJG, Marshall J, Meadows JC, et al. Effect of aspirin in amaurosis fugax. Lancet. 1971;2:743-744.
29. Fields WS, Lemak N, Frankowski R, et al. Controlled trial of aspirin in cerebral ischemia. Stroke. 1977;8:301-306.
30. Barnett HJM. The Canadian Cooperative Study: a randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 1978;299:53-59.
31. Caplan LR. Antiplatelet therapy in stroke prevention: present and future. Cerebrovasc Dis. 2006;21(suppl 1):1-6.
32. Weiss HJ. Antiplatelet therapy. In: Beutler E, Lichtman M, Coller BS, et al, eds. Williams' Hematology, 6th ed. New York: McGraw-Hill; 2001:1763-1776.
33. Moncada S, Vane J. Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl J Med. 1979;300:1142-1147.
34. Nurden AT. Platelet function and pharmacology of antiplatelet drugs. Cerebrovasc Dis. 1997;7(suppl 6):2-9.
35. Moncada C. Biologic and therapeutic potential of prostacyclin. Stroke. 1983;14:157-168.
36. 2 after low dose aspirin. N Engl J Med. 1981;304:76-79.
37. Weksler B, Pelt S, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 1983;308:800-805.
38. Helgason CM, Tortorice L, Winkler S, et al. Aspirin response and failure in cerebral infarction. Stroke. 1993;24:345-350.
39. Coleman JL, Alberts MJ. Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers. Am J Cardiol. 2006;98:838-841.
40. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation. 2007;115:2196-2207.
41. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med. 2007;120:631-635.
42. Hohlfeld T, Weber A-A, Junghans M, et al. Variable platelet response to aspirin in patients with ischemic stroke. Cerebrovasc Dis. 2007;24:43-50.
43. Faraday N, Yanek LR, Mathias R, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation. 2007;115:2490-2496.
44. Ticlopidine [editorial]. Lancet. 1991;337:459-460.
45. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998;129:394-405.
46. Ono S, Ashida S, Abiko Y. Hemorheological effect of ticlopidine in the rat. Thromb Res. 1983;31:549-556.
47. Weksler B. Antiplatelet agents in stroke prevention. Cerebrovasc Dis. 2000;10(suppl 5):41-48.
48. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A report of 60 cases. Ann Intern Med. 1998;128:541-544.
49. Jonas S, Grieco G. An approach to the estimation of the risk of TTP during clopidogrel therapy. Stroke. 2004;35:537-538.
50. Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel vs clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
51. Hankey GJ, Eikelboom JW. Adding aspirin to clopidogrel after TIA and ischemic stroke. Benefits do not match risks. Neurology. 2005;64:1117-1121.
52. Fitzgerald GA. Dipyridamole. N Engl J Med. 1987;316:1247-1257.
53. Atkas B, Utz A, Hoenig-Liedl, et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signalling in human platelets: in vitro and in vivo/ex vivo studies. Stroke. 2003;34:764-769.
54. Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost. 1986;55:12-18.
55. Bult H, Fret HR, Jordaens FH, Herman AG. Dipyridamole potentiates platelet inhibition by nitric oxide. Thromb Haemost. 1991;66:343-349.
56. Honour A, Hockaday T, Mann J. The synergistic effect of aspirin and dipyridamole upon platelet thrombi in living blood vessels. Br J Exp Pathol. 1977;58:268-272.
57. Eisert W. Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells. Neurology. 2001;57:S20-S23.
58. Kim JA, Tran ND, Zhou W, Fisher M. Dipyridamole enhances tissue plasminogen activator release by brain capillary endothelial cells. Thromb Res. 2005;115:435-438.
59. Lepore JJ, Dec GW, Zapol WM, et al. Combined administration of intravenous dipyridamole and inhaled nitric oxide to assess reversibility of pulmonary arterial hypertension in potential cardiac transplant recipients. J Heart Lung Transplant. 2005;11:1950-1956.
60. Gamboa A, Abraham R, Diedrich A, et al. Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole. Stroke. 2005;36:2170-2175.
61. Chen TH, Kao YC, Chen BC, et al. Dipyridamole activation of mitogen-activated protein kinase phosphatase-1 mediates inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression in RAW 264.7 cells. Eur J Phamacol. 2006;541:138-146.
62. Ikeda Y, Kikuchi M, Murakami H. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid, and ticlopidine on platelet function ex vivo: randomized, double-blind cross-over study. Drug Res. 1987;37:563-566.
63. Tanaka K, Ishikawa T, Hagiwara M, et al. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology. 1988;36:313-320.
64. Kwon SU, Cho Y-J, Koo J-S, et al. Cilostazol prevents the progression of the symptomatic intracranial stenosis. The multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36:782-786.
65. Hashimoto A, Miyakoda G, Hirose Y, Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis. 2006;189:350-357.
66. Nakamura K, Ikomi F, Ohhashi T. Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilatation in pressurized rabbit cerebral penetrating arterioles. J Vasc Res. 2006;43:86-94.
67. Simms DS, Merrill-Skoloff G, Furie BC, et al. Initial accumulation of platelets during arterial thrombus formation in vivo is inhibited by elevation of basal cAMP levels. Blood. 2004;103:2127-2134.
68. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
69. Wallace RC, Furlan AJ, Moliterno DJ, et al. Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIb/IIIa receptor inhibitor. AJNR Am J Neuroradiol. 1997;18:1257-1260.
70. Coller BS. Anti GpIIb/IIIa drugs: current status and future directions. Thromb Haemostast. 2001;86:427-443.
71. Dyerberg J, Bang H, Stofferson E, et al. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. Lancet. 1978;2:117-119.
72. Radack K, Deck C, Huster G. Dietary supplementation with low-dose fish oils lowers fibrinogen levels: a randomized double-blind controlled study. Ann Intern Med. 1989;111:757-758.
73. Kobayashi S, Hirai A, Terano T, et al. Reduction in blood viscosity by eicosapentaenoic acid. Lancet. 1981;2:197.
74. Drouet L. Fibrinogen, a treatable risk factor? Cerebrovasc Dis. 1996;6:2-6.
75. Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs. 1997;54(suppl 3):32-40.
76. Rothwell PM, Howard SC, Power DA, et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor stroke. Stroke. 2004;35:2300-2305.
77. Kee DB Jr, Wood JH. Influence of blood rheology on cerebral circulation. In: Wood JH, ed. Cerebral Blood Flow: Physiological and Clinical Aspects. New York: McGraw-Hill; 1987:173-185.
78. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA. 1987;258:1183-1186.
79. Tanne D, Benderly M, Goldbourt U, et al. A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the Bezafibrate Infarction Prevention Study. Am J Med. 2001;111:457-463.
80. Wannamethee SG, Lowe GDO, Whincup PH, et al. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation. 2002;105:1785-1790.
81. Sherman DG: Ancrod. Curr Med Res Opin. 2002;18(suppl 2):s48-s52.
82. Marcade JP, Amarenco P, Capron L. Images d'athero-thrombose. Masson: Issy-les-Moulineaux; 1994.